The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
The clinical and economic burden of chronic obstructive pulmonary disease in the USA
Open accessAbstract
Chronic obstructive pulmonary disease (COPD) is the third most common cause of death in the USA. In 2010, the cost of COPD in the USA was projected to be approximately US$50 billion, which includes $20 billion in indirect costs and $30 billion in direct health care expenditures. These costs can be expected to continue to rise with this progressive disease. Costs increase with increasing severity of disease, and hospital stays account for the majority of these costs. Patients are diagnosed with COPD following a multifactorial assessment that includes spirometry, clinical presentation, symptomatology, and risk factors. Smoking cessation interventions are the most influential factor in COPD management. The primary goal of chronic COPD management is stabilization of chronic disease and prevention of acute exacerbations. Bronchodilators are the mainstay of COPD therapy. Patients with few symptoms and low exacerbation risk should be treated with a short-acting bronchodilator as needed for breathlessness. Progression of symptoms, as well as possible decline in forced expiratory volume in the first second of expiration (FEV1), warrant the use of long-acting bronchodilators. For patients with frequent exacerbations with or without consistent symptoms, inhaled corticosteroids should be considered in addition to a long-acting beta2-agonist (LABA) or long-acting muscarinic antagonist (LAMA) and may even consist of "triple therapy" with all three agents with more severe disease. Phosphodiesterase-4 inhibitors may be an option in patients with frequent exacerbations and symptoms of chronic bronchitis. In addition to a variety of novel ultra-LABAs, LAMAs and combination bronchodilator and inhaled corticosteroid (ICS) therapies, other bronchodilators with a variety of mechanisms are also being considered, to expand therapeutic options for the treatment of COPD. With more than 50 new medications in the pipeline for the treatment of COPD, optimal management will continue to evolve and grow more complex as benefits of therapy are balanced with the limitations and needs of each patient.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Computed Tomography — An Increasing Source of Radiation Exposure
Brenner, D. J., & Hall, E. J. (2007) · New England Journal of Medicine · doi:10.1056/nejmra072149 · Cited by 8,748
Murray, C. J., & Lopez, A. D. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07492-2 · Cited by 7,007
Rehospitalizations among Patients in the Medicare Fee-for-Service Program
Jencks, S. F., Williams, M. V., & Coleman, E. A. (2009) · New England Journal of Medicine · doi:10.1056/nejmsa0803563 · Cited by 5,164
Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease
Calverley, P. M. A., Anderson, J. A., Celli, B., Ferguson, G. T., Jenkins, C., Jones, P. W., Yates, J. C., & Vestbo, J. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063070 · Cited by 3,248
Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease
Hurst, J. R., Vestbo, J., Anzueto, A., Locantore, N., Müllerova, H., Tal-Singer, R., Miller, B., Lomas, D. A., Agusti, A., MacNee, W., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909883 · Cited by 2,981
Bestall, J. C., Paul, E. A., Garrod, R., Garnham, R., Jones, P. W., & Wedzicha, J. A. (1999) · Thorax · doi:10.1136/thx.54.7.581 · Cited by 2,927
The natural history of chronic airflow obstruction.
Fletcher, C., & Peto, R. (1977) · BMJ · doi:10.1136/bmj.1.6077.1645 · Cited by 2,370
A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease
Tashkin, D. P., Celli, B., Senn, S., Burkhart, D., Kesten, S., Menjoge, S., & Decramer, M. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805800 · Cited by 1,604
Connors, A. F., Dawson, N. V., Thomas, C., Harrell, F. E., Desbiens, N., Fulkerson, W. J., Kussin, P., Bellamy, P., Goldman, L., & Knaus, W. A. (1996) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.154.4.8887592 · Cited by 1,393
Anthonisen, N. R. (1994) · JAMA · doi:10.1001/jama.1994.03520190043033 · Cited by 1,341
Ries, A. L., Bauldoff, G. S., Carlin, B. W., Casaburi, R., Emery, C. F., Mahler, D. A., Make, B., Rochester, C. L., ZuWallack, R., & Herrerias, C. (2007) · Chest · doi:10.1378/chest.06-2418 · Cited by 1,306
Azithromycin for prevention of exacerbations of COPD
Albert, R. K., Connett, J., Bailey, W. C., Casaburi, R., Cooper, J. A. D., Criner, G. J., Curtis, J. L., Dransfield, M. T., Han, M. K., Lazarus, S. C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104623 · Cited by 1,226
Calverley, P., Pauwels, R., Vestbo, J., Jones, P., Pride, N., Gulsvik, A., Anderson, J., & Maden, C. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12459-2 · Cited by 1,221
Qaseem, A., Wilt, T. J., Weinberger, S. E., Hanania, N. A., Criner, G., van der Molen, T., Marciniuk, D. D., Denberg, T., Schünemann, H., Wedzicha, W., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-3-201108020-00008 · Cited by 1,087
Chronic obstructive pulmonary disease
Decramer, M., Janssens, W., & Miravitlles, M. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60968-9 · Cited by 972
Bilateral pneumectomy (volume reduction) for chronic obstructive pulmonary disease
Cooper, J. D., Trulock, E. P., Triantafillou, A. N., Patterson, G. A., Pohl, M. S., Deloney, P. A., Sundaresan, R. S., & Roper, C. L. (1995) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(95)70426-4 · Cited by 896
Szafranski, W., Cukier, A., Ramirez, A., Menga, G., Sansores, R., Nahabedian, S., Peterson, S., & Olsson, H. (2003) · European Respiratory Journal · doi:10.1183/09031936.03.00031402 · Cited by 887
Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials
Calverley, P. M., Rabe, K. F., Goehring, U.-M., Kristiansen, S., Fabbri, L. M., & Martinez, F. J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61255-1 · Cited by 829
Wedzicha, J. A., Calverley, P. M. A., Seemungal, T. A., Hagan, G., Ansari, Z., & Stockley, R. A. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200707-973oc · Cited by 827
Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease
Calverley, P. M., Boonsawat, W., Cseke, Z., Zhong, N., Peterson, S., & Olsson, H. (2003) · European Respiratory Journal · doi:10.1183/09031936.03.00027003 · Cited by 730
Mechanisms of Action and Clinical Application of Macrolides as Immunomodulatory Medications
Kanoh, S., & Rubin, B. K. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00078-09 · Cited by 708
Epidemiology and costs of chronic obstructive pulmonary disease
Chapman, K. R., Mannino, D. M., Soriano, J. B., Vermeire, P. A., Buist, A. S., Thun, M. J., Connell, C., Jemal, A., Lee, T. A., Miravitlles, M., et al. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00024505 · Cited by 704
Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPD
Vogelmeier, C., Hederer, B., Glaab, T., Schmidt, H., Rutten-van Mölken, M. P. M. H., Beeh, K. M., Rabe, K. F., & Fabbri, L. M. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008378 · Cited by 684
Complex chronic comorbidities of COPD
Fabbri, L. M., Luppi, F., Beghé, B., & Rabe, K. F. (2008) · European Respiratory Journal · doi:10.1183/09031936.00114307 · Cited by 660 · cited 1×
“COPD is rarely seen in isolation but rather is often managed with comorbidities including heart failure, lung cancer, diabetes, hypertension, and dyslipidemia.(8) Systemic inflammation likely plays a key role in the development of these concomitant disease states, and elevated biomarkers such as C-reactive protein are…”
BackgroundAaron, S. D., Vandemheen, K. L., Fergusson, D., Maltais, F., Bourbeau, J., Goldstein, R., Balter, M., O'Donnell, D., McIvor, A., Sharma, S., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-8-200704170-00152 · Cited by 649
Fabbri, L. M., Calverley, P. M., Izquierdo-Alonso, J. L., Bundschuh, D. S., Brose, M., Martinez, F. J., & Rabe, K. F. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61252-6 · Cited by 614
Donohue, J. F., van Noord, J. A., Bateman, E. D., Langley, S. J., Lee, A., Witek, T. J., Kesten, S., & Towse, L. (2002) · Chest · doi:10.1378/chest.122.1.47 · Cited by 471
Seemungal, T. A. R., Wilkinson, T. M. A., Hurst, J. R., Perera, W. R., Sapsford, R. J., & Wedzicha, J. A. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200801-145oc · Cited by 444
Niewoehner, D. E., Rice, K., Cote, C., Paulson, D., Cooper, J. A. D., Korducki, L., Cassino, C., & Kesten, S. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-5-200509060-00007 · Cited by 436
Brusasco, V (2005) · Thorax · doi:10.1136/thx.2005.brusascolett · Cited by 431
Definition, epidemiology and natural history of COPD
Viegi, G., Pistelli, F., Sherrill, D. L., Maio, S., Baldacci, S., & Carrozzi, L. (2007) · European Respiratory Journal · doi:10.1183/09031936.00082507 · Cited by 430
Qaseem, A., Snow, V., Shekelle, P., Sherif, K., Wilt, T. J., Weinberger, S., Owens, D. K., & for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians* (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-9-200711060-00008 · Cited by 424
Brusasco, V (2003) · Thorax · doi:10.1136/thorax.58.5.399 · Cited by 409
Welte, T., Miravitlles, M., Hernandez, P., Eriksson, G., Peterson, S., Polanowski, T., & Kessler, R. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200904-0492oc · Cited by 408
Screening for and early detection of chronic obstructive pulmonary disease
Soriano, J. B., Zielinski, J., & Price, D. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61290-3 · Cited by 362
van Noord, J. A., Aumann, J.-L., Janssens, E., Smeets, J. J., Verhaert, J., Disse, B., Mueller, A., & Cornelissen, P. J. G. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00140404 · Cited by 341
Miravitlles, M., Guerrero, T., Mayordomo, C., Sánchez-Agudo, L., Nicolau, F., & Segú, J. L. (2000) · Respiration · doi:10.1159/000067462 · Cited by 335
Tantucci, C., & Modina, D. (2012) · International Journal of Chronic Obstructive Pulmonary Disease · doi:10.2147/copd.s27480 · Cited by 321
Kardos, P., Wencker, M., Glaab, T., & Vogelmeier, C. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200602-244oc · Cited by 314
Pharmacoeconomic Evaluation of COPD
Hilleman, D. E., Dewan, N., Malesker, M., & Friedman, M. (2000) · Chest · doi:10.1378/chest.118.5.1278 · Cited by 288
Toy, E. L., Gallagher, K. F., Stanley, E. L., Swensen, A. R., & Duh, M. S. (2010) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.3109/15412555.2010.481697 · Cited by 247
Inflammatory Biomarkers and Comorbidities in Chronic Obstructive Pulmonary Disease
Thomsen, M., Dahl, M., Lange, P., Vestbo, J., & Nordestgaard, B. G. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201206-1113oc · Cited by 245
Jiménez-Ruiz, C. A., Masa, F., Miravitlles, M., Gabriel, R., Viejo, J. L., Villasante, C., & Sobradillo, V. (2001) · Chest · doi:10.1378/chest.119.5.1365 · Cited by 243
Development and Initial Validation of a Self-Scored COPD Population Screener Questionnaire (COPD-PS)
Martinez, F. J., Raczek, A. E., Seifer, F. D., Conoscenti, C. S., Curtice, T. G., D'Eletto, T., Cote, C., Hawkins, C., & Phillips, A. L. (2008) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1080/15412550801940721 · Cited by 236
Early Detection of COPD in a High-Risk Population Using Spirometric Screening
Zieliñski, J., & Bednarek, M. (2001) · CHEST · doi:10.1378/chest.119.3.731 · Cited by 219
Respiratory mechanics in mechanically ventilated patients with respiratory failure
Rossi, A., Gottfried, S. B., Higgs, B. D., Zocchi, L., Grassino, A., & Milic-Emili, J. (1985) · Journal of Applied Physiology · doi:10.1152/jappl.1985.58.6.1849 · Cited by 210
Lung function impairment, COPD hospitalisations and subsequent mortality
Garcia-Aymerich, J., Serra Pons, I., Mannino, D. M., Maas, A. K., Miller, D. P., & Davis, K. J. (2011) · Thorax · doi:10.1136/thx.2010.152876 · Cited by 183
Effects of smoking and smoking cessation on longitudinal decline in pulmonary function.
Burchfiel, C. M., Marcus, E. B., Curb, J. D., Maclean, C. J., Vollmer, W. M., Johnson, L. R., Fong, K. O., Rodriguez, B. L., Masaki, K. H., & Buist, A. S. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.151.6.7767520 · Cited by 180
Time course and pattern of COPD exacerbation onset
Aaron, S. D., Donaldson, G. C., Whitmore, G. A., Hurst, J. R., Ramsay, T., & Wedzicha, J. A. (2012) · Thorax · doi:10.1136/thoraxjnl-2011-200768 · Cited by 179
Singh, D., Brooks, J., Hagan, G., Cahn, A., & O'Connor, B. J. (2008) · Thorax · doi:10.1136/thx.2007.087213 · Cited by 177
Friedman, M., Serby, C. W., Menjoge, S. S., Wilson, J. D., Hilleman, D. E., & Witek, T. J. (1999) · Chest · doi:10.1378/chest.115.3.635 · Cited by 175
Formoterol mono- and combination therapy with tiotropium in patients with COPD: A 6-month study
Vogelmeier, C., Kardos, P., Harari, S., Gans, S. J. M., Stenglein, S., & Thirlwell, J. (2008) · Respiratory Medicine · doi:10.1016/j.rmed.2008.07.020 · Cited by 172
Tiotropium for stable chronic obstructive pulmonary disease
Barr, R. G., Bourbeau, J., & Camargo Jr, C. A. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002876.pub2 · Cited by 159
Tønnesen, P., Mikkelsen, K. L., & Bremann, L. (2006) · CHEST Journal · doi:10.1378/chest.130.2.334 · Cited by 153
Yawn, B. P., Enright, P., Lemanske, R. F., Israel, E., Pace, W. D., Wollan, P. C., & Boushey, H. A. (2007) · CHEST Journal · doi:10.1378/chest.06-2722 · Cited by 148
Body weight and comorbidity predict mortality in COPD patients treated with oxygen therapy
Martí, S., Muñoz, X., Ríos, J., Morell, F., & Ferrer, J. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00076405 · Cited by 141
Pbert, L. A. (2006) · CHEST Journal · doi:10.1378/chest.130.2.314 · Cited by 128
Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease
Appleton, S., Poole, P., Smith, B. J., Veale, A., Lasserson, T. J., Chan, M. M. K., & Cates, C. J. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001104.pub2 · Cited by 119
Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease
Chong, J., Karner, C., & Poole, P. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009157.pub2 · Cited by 107
Effective tobacco dependence treatment
Fiore, M. C. (2002) · JAMA · doi:10.1001/jama.288.14.1768 · Cited by 97
Tashkin, D. P., Donohue, J. F., Mahler, D. A., Huang, H., Goodwin, E., Schaefer, K., Hanrahan, J. P., & Andrews, W. T. (2009) · Respiratory Medicine · doi:10.1016/j.rmed.2008.12.014 · Cited by 68
Antibiotic Prevention of Acute Exacerbations of COPD
Wenzel, R. P., Fowler, A. A., & Edmond, M. B. (2012) · New England Journal of Medicine · doi:10.1056/nejmct1115170 · Cited by 66
Improving the Differential Diagnosis of Chronic Obstructive Pulmonary Disease in Primary Care
Price, D. B., Yawn, B. P., & Jones, R. C. M. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0389 · Cited by 54
Snider, J. T., Romley, J. A., Wong, K. S., Zhang, J., Eber, M., & Goldman, D. P. (2012) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.3109/15412555.2012.696159 · Cited by 53
Melbye, H., Drivenes, Dalbak, Leinan, Ostrem, & Hoegh-Henrichsen (2011) · International Journal of COPD · doi:10.2147/copd.s25955 · Cited by 42
The Role and Potential of Imaging in COPD
Washko, G. R. (2012) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.05.003 · Cited by 32
Utility of COPD Assessment Test (CAT) in primary care consultations: a randomised controlled trial
Gruffydd‐Jones, K., Marsden, H., Holmes, S., Kardos, P., Escamilla, R., Negro, R. D., Roberts, J. A., Nadeau, G. A., Vasselle, M., Leather, D. A., et al. (2013) · Primary Care Respiratory Journal · doi:10.4104/pcrj.2013.00001 · Cited by 28
Mak, G., & Hanania, N. A. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.02.019 · Cited by 21
Readmissions for Chronic Obstructive Pulmonary Disease, 2008: Statistical Brief #121
Elixhauser, A., Dh, A., & Podulka, J. (2011) · Europe PMC (PubMed Central) · Cited by 18
Use of azithromycin in the treatment of acute exacerbations of COPD
Milstone, A. P. (2008) · International Journal of COPD · doi:10.2147/copd.s1189 · Cited by 15
Contemporary surgical management of advanced end stage emphysema: an evidence based review.
Sachithanandan, A., & Badmanaban, B. (2012) · PubMed · Cited by 6
Cited by
Pulmonary rehabilitation for chronic obstructive pulmonary disease
McCarthy, B., Casey, D., Devane, D., Murphy, K., Murphy, E., & Lacasse, Y. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003793.pub3 · Cited by 2,643
Respiration rate and volume measurements using wearable strain sensors
Chu, M., Nguyen, T., Pandey, V., Zhou, Y., Pham, H. N., Bar-Yoseph, R., Radom-Aizik, S., Jain, R., Cooper, D. M., & Khine, M. (2019) · npj Digital Medicine · doi:10.1038/s41746-019-0083-3 · Cited by 403
Ritchie, A. I., & Wedzicha, J. A. (2020) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2020.06.007 · Cited by 402
Economic Burden of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review
Iheanacho, I., Zhang, S., King, D., Rizzo, M., & Ismaila, A. S. (2020) · International Journal of Chronic Obstructive Pulmonary Disease · doi:10.2147/copd.s234942 · Cited by 369
Ford, E. S., Murphy, L. B., Khavjou, O., Giles, W. H., Holt, J. B., & Croft, J. B. (2015) · Chest · doi:10.1378/chest.14-0972 · Cited by 353
Metadata
- Authors
- Ray, S., Guarascio, Finch, & Self, T.
- Venue
- ClinicoEconomics and Outcomes Research
- Publisher
- Informa UK Limited
- Published
- 2013-06
- Volume
- 5
- Pages
- 235
- ISSN
- 1178-6981 (ISSN-L)
- OpenAlex
- W2006430543
- Cited by
- 425
- References
- 73
- FWCI
- 13.64
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.